Background: Patients with some autoimmune diseases (AIDs) are at increased risk of cancer, possibly a result of an underlying dysregulation of the immune system, medication, treatment or, probably, surveillance bias. Data on cancer mortality and survival in patients previously diagnosed with AIDs would provide novel information on these comorbidities and their clinical implications.
introduction
Autoimmune diseases (AIDs) constitute many disease manifestations and many of them are rare but jointly they affect 5%-10% of the population in the developed countries [1] . AIDs are caused by autoreactivity of T cells and/or B cells toward own antigens, either systemically or organ specifically [2] . Risks of defined cancers are increased in groups of AID patients and thus, these patients are more frequent in oncology clinics than is their share in the population. The associations between AID and cancer were initially established for lymphomas, especially non-Hodgkin lymphoma, and rarely myeloma but subsequently alimentary tract cancers have also been incriminated [3] [4] [5] [6] . It is assumed that the immunological disturbances in AIDs may contribute to cancer formation at multiple levels. However, many severe forms of AID manifestations are treated with immunosuppressive therapy for extended periods of time. Immunosuppression is cancer promoting and particularly, virally caused cancers may show large excess risks [7] . On the other hand, some AIDs are treated with prolonged anti-inflammatory medication that is protective of many cancers and in our previous study, decreased risks of colon and rectal cancers in ankylosing spondylitis and rheumatoid arthritis were probably due to this medication [6, 8] .
Even though cancer risk may be truly increased in patients with some AIDs, there is a concern that surveillance bias, due to frequent medical contacts, may contribute at least to the detection of relatively indolent cancers. A likely example on such bias in our previous study was the vastly elevated risks of intestinal carcinoid tumors after many AIDs [6] . Surveillance bias would be, however, unlikely if mortality in cancer was increased. For this reason, in the present follow-up study, we examined standardized mortality ratios (SMRs) for digestive tract cancers in patients who had been hospitalized for any of 33 AIDs, covering the total Swedish population. AID may also affect survival in cancer compared with cancer patients without a diagnosed AID, as has been shown for some AIDs [9] [10] [11] [12] [13] . In the present study, we also follow survival of AID patients using hazard ratios (HRs). An increase in HR shows that the AID decreases the survival. The present data extend our previous study on cancer risks in AID patients [6] .
materials and methods
The research database used in the present study is a subset of the national MigMed 2 datasets at the Center for Primary Health Care Research, Lund University, Malmö, Sweden, also used in the previous study [6] . AID patients were identified from the Swedish Hospital Discharge Register that records complete data on all discharges with dates of hospitalization and diagnoses in some regions since 1964 and nationwide since 1986. The International Classification of Diseases (ICD) codes used were described earlier [14, 15] . A total of 33 diseases were covered. However, autoimmune hemolytic anemia, chorea minor, discoid lupus erythematosus, lupoid hepatitis and Reiter disease had less than five cases each for any cancer and were not significantly associated with any cancer (data are not shown). The linkages were carried out by the use of an individual national identification number that is assigned to each person in Sweden for their lifetime. This number was replaced by a serial number for each person in order to provide anonymity. It should be pointed out that the case numbers in the present study are higher than those in our recent study on relative risks because, by error, the case recruitment was started in 1987 when ICD-9 codes were taken to use and not in 1964 as stated [6] . Because of the small number of fatal cases for some cancer study, histology was not considered in the present.
Cancers were obtained from the nationwide Swedish Cancer Registry. Person-years of follow-up were calculated from date of discharge with the first main diagnosis of AID until death, emigration, or closing date, 31 December 2008. In control analyses, studies to check for the possibility of surveillance biased in patients who underwent treatment, the follow-up was started from the last hospitalization. The used SMR measures the number of cancer deaths in AID patients compared with the controls. SMRs were calculated as the ratio of observed (O) to expected (E) number of cancer-specific deaths. Expected numbers were calculated for anyone not hospitalized for AID. The expected numbers were calculated as age (5-year groups), sex, period (5-year groups), region and socioeconomic status-specific standard incidence rates. Additional adjustments were made for hospitalization for obesity using codes ICD-7 = 287.00, 287.09; ICD-8 = 277.99; ICD-9 = 278A; ICD-10 = E65-E68 (26). A total of 30 020 individuals had been hospitalized for obesity. Similar adjustments were made for smoking using hospitalization for chronic obstructive pulmonary disease as a surrogate with 260 243 individuals affected (codes: ICD-7 = 500-502; ICD-8 = 490-493; ICD-9 = 490-496; ICD-10 = J40-J49) and alcohol using alcoholisms as surrogate (codes: ICD-9 =303; ICD-10=F10.1-F10.9) with 181 862 individuals affected, respectively. Confidence intervals (95% CIs) were calculated assuming a Poisson distribution.
The Cox regression analyses were used to estimate HRs, which could be interpreted as ratios of survival times in the AID patients with cancer compared with the controls, i.e. cancer patients never hospitalized for AID. Adjustments were done as above. The analyses were for cause-specific deaths and deaths from other causes were censored. The proportional hazard assumption for the covariates was tested by Schoenfeld residuals and by plotting the log of the negative log of the survival function versus the log of time. Survival curves for cancer deaths were derived by the Kaplan-Meier method.
The study was approved by the regional ethical review board at Lund.
results
Of the 33 AIDs analyzed, 28 had at least five cases of any of the considered seven cancers and these are shown in the Tables. AIDs are divided in two groups depending on whether they show digestive tract manifestations. Table 1 shows the risks of upper digestive tract, esophageal and stomach cancers.
The SMRs and HRs for upper aerodigestive tract cancer were increased after hospitalization for six and four AIDs with an overall SMR and HR of 1.43 and 1.20. The highest SMRs were seen for Addison disease (4.48) and systemic lupus erythematosus (3.86). The HRs were lower and many not significant for cancers with an increased SMRs. The exception was systemic sclerosis for which only the HR was significant (2.50). The SMR for esophageal cancer was increased also after six AIDs and the HR was increased after four AIDs. Polymyosistis/dermatomyositis showed a high SMR of 6.08 followed by pernicious anemia (3.28). The HRs for esophageal cancer survival were not significant after these disease. The SMR for stomach cancer was increased in five patient groups, whereas the HR was increased in none. The highest SMRs for stomach cancer were recorded after type 1 diabetes (4.47) and pernicious anemia (3.67). SMRs for small intestinal cancers were increased for three cancers and the overall SMR of 1.91 was higher than for any cancer ( Table 2 ). High SMRs were noted for Crohn disease (5.77) and pernicious anemia (5.39); the SMR after celiac disease was even higher but with only one case of small intestinal cancer. The HR for small intestinal cancer was increased after pernicious anemia but even more after Sjögren syndrome (4.91) and Hashimoto/ hypothyroidism (3.64). The SMRs for colon cancer after Crohn disease and ulcerative colitis were high (2.88 and 2.85), alike those for rectal cancers (2.28 and 2.51). However, the HRs were only marginally increased. The HRs for rectal cancer were high after primary biliary cirrhosis (3.22) and Sjögren syndrome (2.27). Notably, the SMR for colon and rectal cancers was significantly decreased after rheumatoid arthritis (0.80 and 0.74), as opposed to HRs (1.29 and 1.28). Anal cancer is a rare cancer but the SMRs were vastly increased after systemic lupus erythematosus (12.43) and localized scleroderma (9.20) and also with increased HRs.
Kaplan-Meier survival plots are shown for colon cancer after four AIDs in Figure 1 . The survival of the control patients was slightly <50% in 10 years. The survival was somewhat better for Crohn disease patients. The 10-year survival of rheumatoid arthritis, multiple sclerosis and polymyositis/dermatomyositis patients was ∼35% but the latter patients has a steep decline in survival in the first 4 years of follow-up. The median ages for colon cancer diagnosis were 70 years for controls and 50 years for Crohn disease, 73 years for rheumatoid arthritis, 66 years for multiple sclerosis and 71 years for polymyositis/ dermatomyositis.
Because the above Kaplan-Meier curve suggested rapid decrease in survival shortly after colon cancer diagnosis, we assessed whether this was the case for other AID cancer combinations as well. Adjusted HRs were calculated for all AIDs for 1 year and 3 years (data not shown). With the exception of polymyositis/dermatomyositis, 1-year HRs for colon cancer were significantly increased after AIDs shown in Figure 1 . However, the rapidly deteriorating survival was not a general phenomenon and the 1-year HRs were higher than the overall HRs for colon and rectal cancers after ulcerative colitis and for rectal cancer after Crohn disease. The end point of the present study was cancer death, defined as the underlying cause of death. Among all main causes of death, cancer deaths have been estimated to be the most reliable, as discussed elsewhere [16] . The used SMR measures the number of cancer deaths in AID patients compared with the controls. The HR measures the timing of cancer deaths in AID patients compared with the controls. A clearly elevated HR should also result in an increased SMR whereas the opposite, an elevated SMR may not influence the HR. In the present study, the control population included any Swedes not hospitalized for an AID. Thus, if an AID did not influence the mortality in the particular cancer, the SMR may be close to the relative risk of that cancer which we reported recently elsewhere [6] ; the SMR may also be lower than the relative risk, which could imply surveillance bias of the particular cancer. The overall SMRs varied between 1.17 and 2.00, which were somewhat lower than the previously reported relative risks and could suggest small effect of the surveillance bias [6] . The SMR was increased for 33 AID cancer pairs compared with 21 HR increases. Below, we will discuss the different outcome options in terms of SMR and HR: both increased, only SMR increased and only HR increased. Increases of both SMR and HR were relatively rare in this study, found for 10 cancers after specific AIDs. Pernicious anemia, systemic lupus erythematosis and psoriasis were each associated with two different cancers. These AIDs were also among those that were most frequently associated with increased risk of cancers [6] . Increased HRs imply that the AID comorbidity affected negatively the survival. Almost all HRs were smaller than the respective SMRs and the HRs rarely exceeded 2.00; a clear exception was anal cancer after localized scleroderma (HR 4.66), however, the case numbers were few. An opposite finding, decreased SMR and increased HRs noted for colon and rectal cancers after rheumatoid arthritis, is likely to be ascribed to the long-term use of anti-inflammatory medication, decreasing the incidence and mortality of colorectal cancers [6, 8] .
Increased SMRs and unchanged HRs were noted for 23 cancers after specific AIDs. In most cases, the increased SMRs were due to the increased incidences of cancer after AIDs and in some cases, the HR results remained inconclusive because of the small numbers of deaths. Myasthenia gravis was earlier noted to increase the incidence of almost all digestive tract cancers and it consequently showed increased SMRs for five cancers but no increases for HRs [6] . In nine cancers, an unchanged SMR was noted with an increased HR. These may signal cases where the AID specifically worsened survival by, e.g. lowering the performance status or limiting therapeutic choices. However, with the exception of esophageal cancer after ulcerative colitis and rheumatoid arthritis, the numbers of deaths were <10 and chance findings were possible. Decreased survival in colorectal cancer after ulcerative colitis has been reported from Denmark and Sweden and in colon cancer after Crohn disease [9, 12] . In the displayed Kaplan-Meier data for colon cancer, the survival was better for Crohn disease than for controls, even though the HR after Crohn disease was 1.13. The likely reason was the younger diagnostic age for colon cancer in Crohn disease patients (50 years) compared with controls (70 years), as young patients have a better survival in colon cancer [17] .
A comparison of the present SMRs with the relative risks in the USA veteran study show highly significant results in both studies, e.g. elevated small intestinal cancer in Crohn disease, elevated stomach and small intestinal cancers in pernicious anemia, elevated esophageal cancer in systemic sclerosis and elevated small intestinal and colon cancers in ulcerative colitis [5] . Some of the elevated risks, such as stomach cancer in pernicious anemia patients and small intestinal and colon cancers risk in inflammatory bowel disease patients, have been noted even earlier, as discussed [5, 6] . However, the elevated SMR of the present study for Figure 1 . Kaplan-Meier survival plots for colon cancer in controls and in patients hospitalized for Crohn disease (CD), rheumatoid arthritis (RA), multiple sclerosis (MS) and polymyositis/dermatomyositis (PM/DM). The numbers of patients and deaths can be seen in Table 2 .
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upper aerodigestive cancers in patients with systemic lupus erythematosis and Hashimoto thyroiditis was not seen in the USA study [5] .
The major limitations of the present study, alluded to earlier, were the small sample size of many AIDs and resulting cancers and the possibility of chance findings because of multiple comparisons. However, the issue of multiple comparisons can mitigated by comparing SMR, HR and relative risks reported in the recent studies [5, 6] . Other limitations were lacking data on AID patients, treatment and on how representative hospitalized patients were.
In conclusion, the SMRs and HRs were increased for 33 and 21 AID cancer pairs, respectively, and were jointly increased for 10 pairs. The increases in SMRs suggest that cancer risk was genuinely increased and that surveillance bias was probably not an important issue. With regard to prognosis, it is unfortunate that so many patients with AIDs have decreased survival and some even with HRs exceeding 2.00. Such data should be considered in the assessment of prognosis and therapeutic planning. 
